Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection ... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Study of a Selective AKT1 E17K Allosteric Inhibitor, ATV-1601, in Patients with Advance... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metast... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Pa... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiov... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More